Page last updated: 2024-11-05

ticlopidine and Ischemia

ticlopidine has been researched along with Ischemia in 92 studies

Ticlopidine: An effective inhibitor of platelet aggregation commonly used in the placement of STENTS in CORONARY ARTERIES.
ticlopidine : A thienopyridine that is 4,5,6,7-tetrahydrothieno[3,2-c]pyridine in which the hydrogen attached to the nitrogen is replaced by an o-chlorobenzyl group.

Ischemia: A hypoperfusion of the BLOOD through an organ or tissue caused by a PATHOLOGIC CONSTRICTION or obstruction of its BLOOD VESSELS, or an absence of BLOOD CIRCULATION.

Research Excerpts

ExcerptRelevanceReference
" The trial was halted after 84% of the anticipated number of patients had been enrolled because the data and safety monitoring board had determined that the combination of clopidogrel and aspirin was associated with both a lower risk of major ischemic events and a higher risk of major hemorrhage than aspirin alone at 90 days."9.27Clopidogrel and Aspirin in Acute Ischemic Stroke and High-Risk TIA. ( Barsan, W; Conwit, RA; Easton, JD; Elm, JJ; Farrant, M; Johnston, SC; Kim, AS; Lindblad, AS; Palesch, YY, 2018)
"The Clopidogrel Versus Aspirin in Patients at Risk of Ischemic Events (CAPRIE) trial was a randomized, blinded, multicenter, trial of 19,185 patients with atherosclerotic disease manifested as recent ischemic stroke or myocardial infarction or symptomatic peripheral arterial disease."9.09Reduction in the need for hospitalization for recurrent ischemic events and bleeding with clopidogrel instead of aspirin. CAPRIE investigators. ( Bhatt, DL; Hacke, W; Hirsch, AT; Ringleb, PA; Topol, EJ, 2000)
"A significant number of ischemic events occur after acute myocardial infarction (MI), even when adhering to dual antiplatelet therapy including aspirin and clopidogrel."7.91The association between clopidogrel and 2-oxo-clopidogrel plasma levels and the long-term clinical outcome after acute myocardial infarction
. ( Apostolovic, S; Konstantinovic, SS; Lilic, J; Nikolic, VN; Pavlovic, M; Stokanovic, D; Zvezdanovic, JB, 2019)
"Clopidogrel is an antiplatelet drug primarily used to treat or prevent acute ischemic stroke (IS) or myocardial infarction (MI)."7.83Association of Cytochrome P450 Genetic Variants with Clopidogrel Resistance and Outcomes in Acute Ischemic Stroke. ( Cheng, W; Chi, L; Lin, J; Wang, C; Wang, Y; Yi, X; Zhou, Q, 2016)
"We tested the hypothesis that clopidogrel and cilostazol combination therapy could effectively attenuate systemic inflammatory reaction, facilitate proliferation of circulating endothelial progenitor cell (EPC), and improve the clinical outcomes of critical limb ischemia (CLI) in patients unsuitable for surgical revascularization or percutaneous transluminal angioplasty (PTA)."7.80Levels and values of lipoprotein-associated phospholipase A2, galectin-3, RhoA/ROCK, and endothelial progenitor cells in critical limb ischemia: pharmaco-therapeutic role of cilostazol and clopidogrel combination therapy. ( Chai, HT; Chang, HW; Chen, CH; Chen, YC; Chen, YL; Chua, S; Chung, SY; Ko, SF; Leu, S; Lin, PY; Sheu, JJ; Sung, PH; Tsai, TH; Yip, HK, 2014)
"Combined cilostazol-clopidogrel therapy is superior to either agent alone in improving ischemia in rodent CLI."7.78Combination of cilostazol and clopidogrel attenuates rat critical limb ischemia. ( Chang, HW; Chen, YL; Chua, S; Leu, S; Lin, KC; Sheu, JJ; Sun, CK; Tsai, CY; Tsai, TH; Yang, JL; Yen, CH; Yip, HK, 2012)
" In this study, we aimed to assess the effects of clopidogrel, an antithrombotic agent, on experimental ischemia-reperfusion model in rats."7.73Protective effects of clopidogrel on oxidant damage in a rat model of acute ischemia. ( Akbas, MH; Berki, KT; Bulbul, S; Kanko, M; Maral, H; Omay, O; Ozden, M; Yavuz, S, 2005)
"The EUCLID trial investigated the effect of monotherapy with ticagrelor versus clopidogrel in 13,885 patients with peripheral artery disease (PAD); the primary endpoint was cardiovascular death, myocardial infarction, or ischaemic stroke."5.27Outcomes of Patients with Critical Limb Ischaemia in the EUCLID Trial. ( Baumgartner, I; Berger, JS; Björck, M; Blomster, JI; Fowkes, FGR; Held, P; Hiatt, WR; Jones, WS; Katona, BG; Mahaffey, KW; Norgren, L; Patel, MR; Rockhold, FW; Wojdyla, DM, 2018)
" The trial was halted after 84% of the anticipated number of patients had been enrolled because the data and safety monitoring board had determined that the combination of clopidogrel and aspirin was associated with both a lower risk of major ischemic events and a higher risk of major hemorrhage than aspirin alone at 90 days."5.27Clopidogrel and Aspirin in Acute Ischemic Stroke and High-Risk TIA. ( Barsan, W; Conwit, RA; Easton, JD; Elm, JJ; Farrant, M; Johnston, SC; Kim, AS; Lindblad, AS; Palesch, YY, 2018)
"In a double-blind randomized controlled trial, 108 patients undergoing infrainguinal revascularization or amputation for critical limb ischemia were maintained on aspirin (75 mg daily) and randomized to clopidogrel (600 mg prior to surgery, and 75 mg daily for 3 days; n = 50) or matched placebo (n = 58)."5.14Randomized controlled trial of dual antiplatelet therapy in patients undergoing surgery for critical limb ischemia. ( Burdess, A; Dawson, AR; Fox, KA; Garden, OJ; Murie, JA; Newby, DE; Nimmo, AF, 2010)
"The Clopidogrel Versus Aspirin in Patients at Risk of Ischemic Events (CAPRIE) trial was a randomized, blinded, multicenter, trial of 19,185 patients with atherosclerotic disease manifested as recent ischemic stroke or myocardial infarction or symptomatic peripheral arterial disease."5.09Reduction in the need for hospitalization for recurrent ischemic events and bleeding with clopidogrel instead of aspirin. CAPRIE investigators. ( Bhatt, DL; Hacke, W; Hirsch, AT; Ringleb, PA; Topol, EJ, 2000)
"Dual antiplatelet therapy of clopidogrel added aspirin is an established treatment strategy to prevent recurrent ischemic event occurrence in coronary artery disease patients."4.89Antiplatelet drug resistance and variability in response: the role of antiplatelet therapy monitoring. ( Gurbel, PA; Tantry, US, 2013)
"In those who have already survived myocardial infarction (MI) or stroke, or have had a transient ischaemic episode (TIA), daily low dose aspirin (ASA) reduces the risk of recurrences by an amount that greatly exceeds the risk of serious bleeding (secondary prevention)."4.88Primary prevention of ischaemic cardiovascular disorders with antiplatelet agents. ( Meade, T, 2012)
" The benefits in mortality and reinfarction were driven by the treatment with prasugrel or ticagrelor, without a significant difference in terms of major bleeding complications as compared to standard-dose clopidogrel (5% vs."4.87Ischaemic and bleeding complications with new, compared to standard, ADP-antagonist regimens in acute coronary syndromes: a meta-analysis of randomized trials. ( Castriota, F; De Luca, G; De Servi, S; Kozinski, M; Kubica, J; Navarese, EP; Schaffer, A; Suriano, P; Verdoia, M, 2011)
"Patients with acute coronary syndromes and patients who undergo coronary stent implantation frequently receive dual antiplatelet therapy with aspirin and a thienopyridine."4.85Monitoring platelet function to reduce the risk of ischemic and bleeding complications. ( Price, MJ, 2009)
"To review the rationale, clinical practice guideline recommendations, and clinical trial data describing bleeding and clinical outcomes associated with the use of the combination of aspirin, a thienopyridine, and warfarin."4.84Aspirin, clopidogrel, and warfarin: is the combination appropriate and effective or inappropriate and too dangerous? ( Hermosillo, AJ; Spinler, SA, 2008)
" For patients with disabling intermittent claudication who do not respond to conservative measures and who are not candidates for surgical or catheter-based intervention, we suggest cilostazol (Grade 2A)."4.82Antithrombotic therapy in peripheral arterial occlusive disease: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. ( Clagett, GP; Jackson, MR; Lip, GY; Sobel, M; Tangelder, M; Verhaeghe, R, 2004)
"A significant number of ischemic events occur after acute myocardial infarction (MI), even when adhering to dual antiplatelet therapy including aspirin and clopidogrel."3.91The association between clopidogrel and 2-oxo-clopidogrel plasma levels and the long-term clinical outcome after acute myocardial infarction
. ( Apostolovic, S; Konstantinovic, SS; Lilic, J; Nikolic, VN; Pavlovic, M; Stokanovic, D; Zvezdanovic, JB, 2019)
"Data on the clinical impact of gender in "real-life" patients with acute coronary syndrome (ACS) undergoing percutaneous coronary intervention (PCI), receiving clopidogrel, prasugrel, or ticagrelor are limited."3.85Gender-related differences in antiplatelet treatment patterns and outcome: Insights from the GReekAntiPlatElet Registry. ( Alexopoulos, D; Davlouros, P; Deftereos, S; Goudevenos, J; Hamilos, M; Kanakakis, I; Lekakis, J; Sitafidis, G; Vavouranakis, M; Xanthopoulou, I, 2017)
"Clopidogrel is an antiplatelet drug primarily used to treat or prevent acute ischemic stroke (IS) or myocardial infarction (MI)."3.83Association of Cytochrome P450 Genetic Variants with Clopidogrel Resistance and Outcomes in Acute Ischemic Stroke. ( Cheng, W; Chi, L; Lin, J; Wang, C; Wang, Y; Yi, X; Zhou, Q, 2016)
"This study was conducted to determine whether there is additive benefit of dual-antiplatelet therapy (DAPT) with aspirin (acetylsalicylic acid [ASA]) and clopidogrel compared with ASA monotherapy among patients with symptomatic peripheral arterial disease."3.81Association of dual-antiplatelet therapy with reduced major adverse cardiovascular events in patients with symptomatic peripheral arterial disease. ( Amsterdam, EA; Anderson, DR; Armstrong, EJ; Bang, H; Freischlag, JA; Laird, JR; Singh, GD; Yeo, KK, 2015)
"In a novel application, we prospectively monitored ischemic, bleeding, and mortality outcomes among patients initiating prasugrel versus clopidogrel in routine care during the first 2 years following the approval of prasugrel."3.80Near-real-time monitoring of new drugs: an application comparing prasugrel versus clopidogrel. ( Bohn, RL; Choudhry, NK; Daniel, GW; Gagne, JJ; Liu, J; Patrick, AR; Rassen, JA; Schneeweiss, S; Sridhar, G, 2014)
"We tested the hypothesis that clopidogrel and cilostazol combination therapy could effectively attenuate systemic inflammatory reaction, facilitate proliferation of circulating endothelial progenitor cell (EPC), and improve the clinical outcomes of critical limb ischemia (CLI) in patients unsuitable for surgical revascularization or percutaneous transluminal angioplasty (PTA)."3.80Levels and values of lipoprotein-associated phospholipase A2, galectin-3, RhoA/ROCK, and endothelial progenitor cells in critical limb ischemia: pharmaco-therapeutic role of cilostazol and clopidogrel combination therapy. ( Chai, HT; Chang, HW; Chen, CH; Chen, YC; Chen, YL; Chua, S; Chung, SY; Ko, SF; Leu, S; Lin, PY; Sheu, JJ; Sung, PH; Tsai, TH; Yip, HK, 2014)
" Patients with critical limb ischemia following stent thrombosis were included if dual antiplatelet therapy consisting of 100 mg aspirin and 75 mg clopidogrel per day had been administered over three months prior to enrollment."3.80Response to dual antiplatelet therapy in patients with peripheral artery occlusive disease suffering from critical limb ischemia. ( Baecker, C; Baro, D; Meybohm, P; Mutlak, H; Schmitz-Rixen, T; Wand, S; Weber, CF; Zacharowski, K, 2014)
" This study evaluated the results of infrainguinal endovascular procedures performed for critical ischemia, in accordance with patient compliance to clopidogrel treatment."3.79Platelet antiaggregation therapy and subinguinal endovascular revascularization. ( Aleil, B; Chakfe, N; Geny, B; Kretz, JG; Lejay, A; Stephan, D; Thaveau, F, 2013)
"Ninety-minute ischemia before vein grafting can cause serious EC loss, but does not increase early intimal hyperplasia when clopidogrel is administered."3.78Influence of ischemia before vein grafting on early hyperplasia of the graft and the dynamic changes of the intima after grafting. ( Guo, Q; Lu, Z; Sun, M; Zou, R, 2012)
"Combined cilostazol-clopidogrel therapy is superior to either agent alone in improving ischemia in rodent CLI."3.78Combination of cilostazol and clopidogrel attenuates rat critical limb ischemia. ( Chang, HW; Chen, YL; Chua, S; Leu, S; Lin, KC; Sheu, JJ; Sun, CK; Tsai, CY; Tsai, TH; Yang, JL; Yen, CH; Yip, HK, 2012)
"Clopidogrel responsiveness has been proposed to be involved in recurrent ischemic events after stenting for non-ST elevation acute coronary syndromes (NSTE ACS)."3.74ADP-induced platelet aggregation and platelet reactivity index VASP are good predictive markers for clinical outcomes in non-ST elevation acute coronary syndrome. ( Alessi, MC; Bonnet, JL; Camoin, L; Carvajal, J; Cuisset, T; Frere, C; Juhan-Vague, I; Lambert, M; Morange, PE; Quilici, J, 2007)
"We studied 137 patients undergoing antiplatelet therapy with clopidogrel and 336 patients with aspirin for the occurrence of neurological events (ischemic stroke and/or carotid revascularization)."3.73Association of a functional polymorphism in the clopidogrel target receptor gene, P2Y12, and the risk for ischemic cerebrovascular events in patients with peripheral artery disease. ( Amighi, J; Brunner, M; Exner, M; Felber, K; Funk, M; Mannhalter, C; Minar, E; Mlekusch, W; Müller, M; Sabeti, S; Schillinger, M; Ziegler, S, 2005)
" In this study, we aimed to assess the effects of clopidogrel, an antithrombotic agent, on experimental ischemia-reperfusion model in rats."3.73Protective effects of clopidogrel on oxidant damage in a rat model of acute ischemia. ( Akbas, MH; Berki, KT; Bulbul, S; Kanko, M; Maral, H; Omay, O; Ozden, M; Yavuz, S, 2005)
"To assess the effect of ticlopidine on the cutaneous circulation, 25 patients with lower limb ischemia were investigated just before and at two hours after being given a 200 mg oral dose of ticlopidine."3.68Effect of ticlopidine on the cutaneous circulation in peripheral vascular disease. ( Iwai, T; Qian, S, 1993)
"Peripheral artery disease is considered to be a manifestation of systemic atherosclerosis with associated adverse cardiovascular and limb events."2.84Ticagrelor versus Clopidogrel in Symptomatic Peripheral Artery Disease. ( Baumgartner, I; Berger, JS; Blomster, J; Fowkes, FG; Heizer, G; Held, P; Hiatt, WR; Jones, WS; Katona, BG; Mahaffey, KW; Millegård, M; Norgren, L; Patel, MR; Reist, C, 2017)
"Twenty patients with ≥50 % angiographic stenosis of the SFA had blood drawn just proximal to the lesion and from a contralateral site free of disease."2.78Increased local cytokine production at culprit superficial femoral artery plaques. ( Adams, JE; Ashikaga, T; Bertges, DJ; Dauerman, HL; Donaldson, CW; Elgharib, NZ; Mueller, EL; Prabhu, W; Schneider, DJ, 2013)
"Between June 2008 and May 2009, 88 consecutive patients referred for EVT were randomly divided into a clopidogrel group (42 cases) and a clopidogrel combined with warfarin group (46 cases) before the procedure."2.78A prospective randomized controlled clinical trial on clopidogrel combined with warfarin versus clopidogrel alone in the prevention of restenosis after endovascular treatment of the femoropopliteal artery. ( Feng, Y; Guo, M; Li, H; Liang, G; Luo, X; Zhang, C; Zhang, F, 2013)
"In the peripheral arteries, a thrombus superimposed on atherosclerosis contributes to the progression of peripheral artery disease (PAD), producing intermittent claudication (IC), ischemic necrosis, and, potentially, loss of the limb."2.50Systematic reviews and meta-analyses for more profitable strategies in peripheral artery disease. ( Cafaro, G; de Gaetano, G; Di Minno, A; Di Minno, G; Lupoli, R; Petitto, M; Spadarella, G; Tremoli, E, 2014)
" The comparator was standard dosage of clopidogrel."2.49Comparing newer oral anti-platelets prasugrel and ticagrelor in reduction of ischemic events-evidence from a network meta-analysis. ( Chatterjee, S; Frankel, R; Ghose, A; Guha, G; Mukherjee, D; Sharma, A, 2013)
"Fundamentally, acute coronary syndromes are platelet-centric diseases, resulting from platelet-rich thrombi that develop at the site of vessel wall injury."2.44The rationale for and comparisons of different antiplatelet treatments in acute coronary syndrome. ( Gurbel, PA; Tantry, US, 2008)
"Atherothrombosis is a generalized and progressive process with an inflammatory component."2.44Role of antiplatelet agents in the primary and secondary prevention of atherothrombotic events in high risk-patients. ( Ellahham, S, 2008)
"Atorvastatin 80 mg was found to be independent predictor of survival, and major amputation was found to be independent predictor of mortality."1.39Long-term results of plaque excision combined with aggressive pharmacotherapy in high-risk patients with advanced peripheral artery disease (SAVE a LEG registry). ( Buszman, PE; Buszman, PP; Kiesz, RS; Konkolewska, MD; Martin, JL; Radvany, MG; Szymanski, R; Wiernek, BK; Wiernek, SL, 2013)
"We compared patients undergoing PCI who received aspirin and clopidogrel loading dose in addition to either conventional bivalirudin dosing (intravenous [IV] bolus of 0."1.38Comparison of bolus only with bolus plus infusion of bivalirudin in patients undergoing elective percutaneous coronary intervention: a retrospective observational study. ( Ghosn, S; Sheikh-Taha, M, 2012)
"We report a case of spontaneous spinal epidural hematoma (SSEH) in a 60-yr-old woman who was treated with clopidogrel for frequent transient ischemic attacks."1.34Clopidogrel-induced spontaneous spinal epidural hematoma. ( Hong, JT; Lee, SW; Son, BC; Sung, JH, 2007)
"Ten patients with traumatic dissection underwent stenting."1.33Endovascular stent-assisted angioplasty in the management of traumatic internal carotid artery dissections. ( Ben-Hur, T; Cohen, JE; Gomori, JM; Rajz, G; Umansky, F, 2005)

Research

Studies (92)

TimeframeStudies, this research(%)All Research%
pre-19903 (3.26)18.7374
1990's6 (6.52)18.2507
2000's30 (32.61)29.6817
2010's52 (56.52)24.3611
2020's1 (1.09)2.80

Authors

AuthorsStudies
Ahmed, S1
Gul, S1
Siraj, S1
Hussain, A1
Sheikh, FS1
Shah, SU1
Janjua, K1
Khan, H1
Hamdard, MH1
Qiao, M1
Bi, Q1
Fu, P1
Wang, Y2
Song, Z1
Guo, F1
Xanthopoulou, I1
Davlouros, P1
Deftereos, S1
Hamilos, M1
Sitafidis, G1
Kanakakis, I1
Vavouranakis, M1
Goudevenos, J1
Lekakis, J1
Alexopoulos, D1
Norgren, L2
Patel, MR2
Hiatt, WR2
Wojdyla, DM1
Fowkes, FGR1
Baumgartner, I2
Mahaffey, KW2
Berger, JS2
Jones, WS2
Katona, BG2
Held, P2
Blomster, JI1
Rockhold, FW1
Björck, M1
Bath, PM1
Woodhouse, LJ1
Appleton, JP1
Beridze, M1
Christensen, H1
Dineen, RA1
Duley, L1
England, TJ1
Flaherty, K1
Havard, D1
Heptinstall, S1
James, M1
Krishnan, K1
Markus, HS1
Montgomery, AA1
Pocock, SJ1
Randall, M1
Ranta, A1
Robinson, TG1
Scutt, P1
Venables, GS1
Sprigg, N1
Johnston, SC2
Easton, JD2
Farrant, M1
Barsan, W1
Conwit, RA1
Elm, JJ1
Kim, AS1
Lindblad, AS1
Palesch, YY1
Lewis, SR1
Pritchard, MW1
Schofield-Robinson, OJ1
Alderson, P1
Smith, AF1
Pavlovic, M1
Apostolovic, S1
Stokanovic, D1
Lilic, J1
Konstantinovic, SS1
Zvezdanovic, JB1
Nikolic, VN1
Lejay, A1
Thaveau, F1
Aleil, B1
Geny, B1
Kretz, JG1
Stephan, D1
Chakfe, N1
Li, H1
Zhang, F1
Liang, G1
Luo, X1
Zhang, C1
Feng, Y1
Guo, M1
Bennett, D1
Yan, B1
Siller-Matula, JM1
Jilma, B1
Gagne, JJ1
Rassen, JA1
Choudhry, NK1
Bohn, RL1
Patrick, AR1
Sridhar, G1
Daniel, GW1
Liu, J1
Schneeweiss, S1
Sheu, JJ2
Lin, PY1
Sung, PH1
Chen, YC1
Leu, S2
Chen, YL2
Tsai, TH2
Chai, HT1
Chua, S2
Chang, HW2
Chung, SY1
Chen, CH1
Ko, SF1
Yip, HK2
Spiliopoulos, S1
Di Minno, G1
Spadarella, G1
Cafaro, G1
Petitto, M1
Lupoli, R1
Di Minno, A1
de Gaetano, G1
Tremoli, E1
Alosh, M1
Huque, MF1
Koch, GG1
Polzin, A2
Schleicher, M1
Seidel, H1
Scharf, RE1
Merx, MW1
Kelm, M2
Zeus, T2
Wand, S1
Baro, D1
Baecker, C1
Meybohm, P1
Schmitz-Rixen, T1
Zacharowski, K1
Mutlak, H1
Weber, CF1
Sun, B1
Li, J1
Dong, M1
Yang, L1
Wu, C1
Zhu, L1
Cong, YL1
Armstrong, EJ1
Anderson, DR1
Yeo, KK1
Singh, GD1
Bang, H1
Amsterdam, EA1
Freischlag, JA1
Laird, JR1
Afzal, S1
Balzer, J1
Rassaf, T1
Yi, X1
Lin, J1
Zhou, Q1
Wang, C1
Cheng, W1
Chi, L1
Dake, MD1
Ansel, GM1
Jaff, MR1
Ohki, T1
Saxon, RR1
Smouse, HB1
Machan, LS1
Snyder, SA1
O'Leary, EE1
Ragheb, AO1
Zeller, T1
Domanski, MJ1
Zhao, Z1
Li, X1
Sun, S1
Mei, S1
Ma, N1
Miao, Z1
Zhao, M1
Peng, S1
Fichter, AM1
Ritschl, LM1
Robitzky, LK1
Wagenpfeil, S1
Mitchell, DA1
Wolff, KD1
Mücke, T1
Fowkes, FG1
Heizer, G1
Blomster, J1
Millegård, M1
Reist, C1
Thott, O1
Granath, F1
Malmstedt, J1
Wahlgren, CM1
Zimmermann, N1
Hohlfeld, T1
Gurbel, PA2
Tantry, US2
Price, MJ1
Mohler, ER1
Angiolillo, DJ1
Suryadevara, S1
Raynaud, A1
Novelli, L1
Rovani, X1
Carreres, T1
Bourquelot, P1
Hermelin, A1
Angel, C1
Beyssen, B1
Collet, JP1
Montalescot, G3
Nikolsky, E1
Stone, GW1
Kirtane, AJ1
Dangas, GD1
Lansky, AJ1
McLaurin, B1
Lincoff, AM2
Feit, F1
Moses, JW1
Fahy, M1
Manoukian, SV1
White, HD1
Ohman, EM1
Bertrand, ME1
Cox, DA1
Mehran, R1
Dedaj, R1
Levy, W1
Tacke, J1
Lindhoff-Last, E1
Mousa, SA1
Jeske, WP1
Fareed, J1
Adams, HP1
Burdess, A2
Nimmo, AF2
Garden, OJ2
Murie, JA2
Dawson, AR2
Fox, KA4
Newby, DE2
Breet, NJ1
VAN Werkum, JW1
Bouman, HJ1
Kelder, JC1
Ten Berg, JM1
Hackeng, CM1
Hwang, SJ1
Jeong, YH1
Kim, IS1
Park, KS1
Kang, MK1
Koh, JS1
Park, JR1
Park, Y1
Koh, EH1
Kwak, CH1
Hwang, JY1
Kim, S1
Conrad, MF1
Crawford, RS1
Hackney, LA1
Paruchuri, V1
Abularrage, CJ1
Patel, VI1
Lamuraglia, GM1
Cambria, RP1
Morofuji, Y1
So, G1
Hiu, T1
Kawakubo, J1
Hayashi, K1
Kitagawa, N1
Morikawa, M1
Suyama, K1
Nagata, I1
Navarese, EP1
Verdoia, M1
Schaffer, A1
Suriano, P1
Kozinski, M1
Castriota, F1
De Servi, S1
Kubica, J1
De Luca, G1
Zhang, HL1
Chen, XB1
Fan, ZY1
Wu, J1
Kwon, SU1
Hong, KS1
Kang, DW1
Park, JM1
Lee, JH1
Cho, YJ1
Yu, KH1
Koo, JS1
Wong, KS1
Lee, SH1
Lee, KB1
Kim, DE1
Jeong, SW1
Bae, HJ1
Lee, BC1
Han, MK1
Rha, JH1
Kim, HY1
Mok, VC1
Lee, YS1
Kim, GM1
Suwanwela, NC1
Yun, SC1
Nah, HW1
Kim, JS1
Aw, D1
Sharma, JC1
Meves, SH1
Overbeck, U1
Endres, HG1
Krogias, C1
Neubauer, H1
Bhatt, DL5
Paré, G1
Eikelboom, JW1
Simonsen, KL1
Emison, ES1
Steg, PG2
Bhakta, N1
Hacke, W4
Flather, MD2
Mak, KH2
Cacoub, P2
Creager, MA2
Berger, PB2
Steinhubl, SR2
Murugesan, G1
Mehta, SR1
Kottke-Marchant, K1
Topol, EJ4
Sheikh-Taha, M1
Ghosn, S1
Lin, KC1
Tsai, CY1
Yen, CH1
Sun, CK1
Yang, JL1
Meade, T1
Zou, R1
Sun, M1
Lu, Z1
Guo, Q1
Kiesz, RS1
Wiernek, SL1
Wiernek, BK1
Radvany, MG1
Buszman, PP1
Szymanski, R1
Konkolewska, MD1
Martin, JL1
Buszman, PE1
Chatterjee, S1
Ghose, A1
Sharma, A1
Guha, G1
Mukherjee, D1
Frankel, R1
Donaldson, CW1
Schneider, DJ1
Bertges, DJ1
Adams, JE1
Elgharib, NZ1
Mueller, EL1
Prabhu, W1
Ashikaga, T1
Dauerman, HL1
Avegliano, G1
Evangelista, A1
Elorz, C1
González-Alujas, T1
García del Castillo, H1
Soler-Soler, J1
Rao, U1
Weston, C1
Clagett, GP1
Sobel, M1
Jackson, MR1
Lip, GY1
Tangelder, M1
Verhaeghe, R1
Jones, L1
Griffin, S1
Palmer, S1
Main, C1
Orton, V1
Sculpher, M1
Sudlow, C1
Henderson, R1
Hawkins, N1
Riemsma, R1
Kanko, M1
Maral, H1
Akbas, MH1
Ozden, M1
Bulbul, S1
Omay, O1
Yavuz, S1
Berki, KT1
Cohen, JE1
Ben-Hur, T1
Rajz, G1
Umansky, F1
Gomori, JM1
Ziegler, S1
Schillinger, M1
Funk, M1
Felber, K1
Exner, M1
Mlekusch, W1
Sabeti, S1
Amighi, J1
Minar, E1
Brunner, M1
Müller, M1
Mannhalter, C1
Vinholt, P1
Poulsen, TS1
Korsholm, L1
Kristensen, SR1
Hallas, J1
Damkier, P1
Mickley, H1
Black, HR1
Boden, WE1
Cohen, EA1
Haffner, SM1
Hamm, CW1
Hankey, GJ1
Mas, JL1
Pearson, TA1
Weber, MA1
Booth, J1
Norris, JW1
Barnett, HJ1
Collins, P1
Ford, I1
Greaves, M1
Macaulay, E1
Brittenden, J1
Heeg, B1
van Gestel, A1
Hout, Bv1
Olsen, J1
Haghfelt, TH1
Sung, JH1
Hong, JT1
Son, BC1
Lee, SW1
Frere, C1
Cuisset, T1
Quilici, J1
Camoin, L1
Carvajal, J1
Morange, PE1
Lambert, M1
Juhan-Vague, I1
Bonnet, JL1
Alessi, MC1
Ellahham, S1
Andreozzi, GM1
Arosio, E1
Martini, R1
Verlato, F1
Visonà, A1
Hermosillo, AJ1
Spinler, SA1
Katsumura, T2
Mishima, Y1
Kamiya, K1
Sakaguchi, S1
Tanabe, T1
Sakuma, A1
Qian, S1
Iwai, T1
Born, GV1
Collins, R1
Dippel, DW1
D'Sa, S1
Machin, SJ1
Watson, HR1
Belcher, G1
Horrocks, M1
Kobza, II1
Hirsch, AT2
Ringleb, PA2
Chew, DP1
Gusak, VK1
Shtutin, AA1
Rodin, IuV1
Il'iushchenko, SV1
Iurchuk, AIu1
Undas, A1
Bazan-Socha, S1
Swadzba, J1
Musial, J1
Lièvre, M1
Chirossel, P1
Adenis, T1
Amiel, M1
Boissel, JP1

Clinical Trials (17)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
A Randomized, Double-blind, Parallel Group, Multicentre Phase IIIb Study to Compare Ticagrelor With Clopidogrel Treatment on the Risk of Cardiovascular Death, Myocardial Infarction and Ischemic Stroke in Patients With Established Peripheral Artery Disease[NCT01732822]Phase 313,885 participants (Actual)Interventional2012-12-04Completed
Platelet-Oriented Inhibition in New TIA and Minor Ischemic Stroke (POINT) Trial[NCT00991029]Phase 34,881 participants (Actual)Interventional2010-05-28Terminated (stopped due to The trial was halted by the DSMB.)
Trial of PCSK9 Inhibition in Patients With Acute Stroke and Symptomatic Intracranial Atherosclerosis - a Prospective, Randomized, Open-label, Blinded End-point Study With High-resolution MR Vessel Wall Imaging[NCT05001984]Phase 260 participants (Anticipated)Interventional2021-08-01Recruiting
Early Intensive Medical Therapy for the Prevention of Early Neurological Deterioration in Branch Atheromatous Disease[NCT04824911]Phase 2424 participants (Anticipated)Interventional2021-03-23Recruiting
Comparison of Clopidogrel-based Antiplatelet Therapy Versus Warfarin as Secondary Prevention Strategy for AntiPhospholipid Syndrome-related STROKE (APS-STROKE)[NCT05995600]Phase 4400 participants (Anticipated)Interventional2023-12-31Not yet recruiting
Genotype Guided Antiplatelet Therapy In Ischemic Stroke[NCT05763862]350 participants (Anticipated)Interventional2023-04-24Recruiting
A REAl-life Study on Short-term Dual Antiplatelet Treatment in Patients With Ischemic Stroke or Transient Ischemic Attack[NCT05476081]1,067 participants (Anticipated)Observational [Patient Registry]2021-02-03Recruiting
Associations of the Pharmacogenetic and Pharmacokinetic Factors With Clopidogrel Low Response and Clinical Outcome in Patients With Coronary Stent Implantation: a Registration Study[NCT01968499]1,805 participants (Actual)Observational [Patient Registry]2011-03-31Completed
Study of the Efficacy and Safety of Cilostazol in the Prevention of Ischemic Vascular Events in Diabetic Patients With Symptomatic Peripheral Artery Disease.[NCT02983214]Phase 4826 participants (Actual)Interventional2016-11-30Completed
A Multicenter, Randomized, Controlled, Superiority Clinical Trial to Evaluate the Safety and Efficacy of Drug-eluting Peripheral Arterial Stent System(G-stream) in the Treatment of the Above-the-knee Femoropopliteal Artery Stenosis or Occlusion[NCT05780359]280 participants (Anticipated)Interventional2022-05-27Recruiting
Evaluation of the Zilver PTX Drug-Eluting Stent in the Above-the-Knee Femoropopliteal Artery[NCT00120406]474 participants (Actual)Interventional2005-03-31Completed
REACTIC-TAVI Trial: Platelet REACtivity According to TICagrelor Dose After Transcatheter AorticValve Implantation. A Pilot Study.[NCT04331145]Phase 440 participants (Actual)Interventional2020-06-23Completed
CYP 2C19 Polymorphism and Response to Adjunctive Cilostazol and High Maintenance-dose Clopidogrel in Patients Undergoing Elective Percutaneous Coronary Intervention[NCT01012193]Phase 4134 participants (Actual)Interventional2008-01-31Completed
Trial for Efficacy and Safety of Cilostazol on the Progression of Symptomatic Intracranial Stenosis Comparing Clopidogrel[NCT00130039]Phase 4457 participants (Actual)Interventional2005-08-31Completed
Prevalence of Low Response to Clopidogrel in Patients After Acute Ischemic Stroke.[NCT01843361]159 participants (Actual)Observational2010-07-31Completed
A Phase III, Multicenter, Multinational, Randomized, Parallel Group, Double-blind Trial of Clopidogrel Versus Placebo in High-risk Patients Aged 45 Years and Older, at Risk of Atherothrombotic Events, and Who Are Receiving Background Therapy Including Low[NCT00050817]Phase 315,603 participants (Actual)Interventional2002-10-31Completed
Clopidogrel After Surgery for Coronary Artery Disease (CASCADE Trial): Does Clopidogrel Prevent Saphenous Vein Graft Disease After Coronary Bypass?[NCT00228423]Phase 2113 participants (Actual)Interventional2006-05-31Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

ALI

Participants with ALI. If no event, censoring occurs at the minimum of (PACD, last endpoint assessment date, death date) (NCT01732822)
Timeframe: From randomization to PACD, an average of 2.5 years

InterventionParticipant (Number)
Ticagrelor 90 mg bd117
Clopidogrel 75 mg od115

All-cause Mortality

Participants with all-cause death. If no event, censoring occurs at the minimum of (PACD, last endpoint assessment date) (NCT01732822)
Timeframe: From randomization to PACD, an average of 2.5 years

InterventionParticipant (Number)
Ticagrelor 90 mg bd628
Clopidogrel 75 mg od635

Any Amputation Caused by PAD

Participants with any amputation caused by peripheral arterial disease (PAD). If no event, censoring occurs at the minimum of (PACD, last endpoint assessment date, death date) (NCT01732822)
Timeframe: From randomization to PACD, an average of 2.5 years

InterventionParticipant (Number)
Ticagrelor 90 mg bd179
Clopidogrel 75 mg od208

Any Revascularisation (Coronary, Peripheral [Limb, Mesenteric, Renal, Carotid and Other])

Participants with any revascularization. If no event, censoring occurs at the minimum of (PACD, last endpoint assessment date, death date) (NCT01732822)
Timeframe: From randomization to PACD, an average of 2.5 years

InterventionParticipant (Number)
Ticagrelor 90 mg bd1211
Clopidogrel 75 mg od1250

Composite of Cardiovascular (CV) Death/MI/Ischemic Stroke

Participants with CV death, myocardial infarction (MI) or ischemic stroke. If no event, censoring occurs at the minimum of (primary analysis censoring date (PACD), last endpoint assessment date, non-CV death date) (NCT01732822)
Timeframe: From randomization to PACD, an average of 2.5 years

InterventionParticipants (Number)
Ticagrelor 90 mg bd751
Clopidogrel 75 mg od740

Composite of CV Death, MI, and All-cause Stroke (Ischemic or Hemorrhagic)

Participants with CV death, MI or all-cause stroke. If no event, censoring occurs at the minimum of (PACD, last endpoint assessment date, non-CV death date) (NCT01732822)
Timeframe: From randomization to PACD, an average of 2.5 years

InterventionParticipant (Number)
Ticagrelor 90 mg bd766
Clopidogrel 75 mg od759

Composite of CV Death, MI, Ischemic Stroke, and ALI

Participants with CV death, MI, ischemic stroke or acute limb ischemia (ALI). If no event, censoring occurs at the minimum of (PACD, last endpoint assessment date, non-CV death date) (NCT01732822)
Timeframe: From randomization to PACD, an average of 2.5 years

InterventionParticipant (Number)
Ticagrelor 90 mg bd839
Clopidogrel 75 mg od833

CV Death

Participants with CV death. If no event, censoring occurs at the minimum of (PACD, last endpoint assessment date, non-CV death date) (NCT01732822)
Timeframe: From randomization to PACD, an average of 2.5 years

InterventionParticipant (Number)
Ticagrelor 90 mg bd363
Clopidogrel 75 mg od343

CV-related Hospitalization

Participants with hospitalization associated with CV death, hospitalization due to MI, ischemic stroke, lower extremity revascularization, major amputation due to PAD, transient ischemic attack (TIA), coronary revascularization or unstable angina. If no event, censoring occurs at the minimum of (PACD, last endpoint assessment date, death date) (NCT01732822)
Timeframe: From randomization to PACD, an average of 2.5 years

InterventionParticipant (Number)
Ticagrelor 90 mg bd1312
Clopidogrel 75 mg od1314

Lower Extremity Revascularization

Participants with lower extremity revascularization (LER). If no event, censoring occurs at the minimum of (PACD, last endpoint assessment date, death date) (NCT01732822)
Timeframe: From randomization to PACD, an average of 2.5 years

InterventionParticipant (Number)
Ticagrelor 90 mg bd846
Clopidogrel 75 mg od892

Major Amputation Caused by PAD

Participants with major amputation caused by PAD. If no event, censoring occurs at the minimum of (PACD, last endpoint assessment date, death date) (NCT01732822)
Timeframe: From randomization to PACD, an average of 2.5 years

InterventionParticipant (Number)
Ticagrelor 90 mg bd100
Clopidogrel 75 mg od116

MI

Participants with MI. If no event, censoring occurs at the minimum of (PACD, last endpoint assessment date, death date) (NCT01732822)
Timeframe: From randomization to PACD, an average of 2.5 years

InterventionParticipant (Number)
Ticagrelor 90 mg bd349
Clopidogrel 75 mg od334

Net Clinical Benefit (Composite of All-cause Mortality/MI/Ischemic Stroke/ALI/Major Amputation/Fatal Bleeding/Intracranial Bleeding)

Participants with all-cause death, MI, ischemic stroke, ALI, major amputation, fatal bleeding or intracranial bleeding. If no event, censoring occurs at the minimum of (PACD, last endpoint assessment date) (NCT01732822)
Timeframe: From randomization to PACD, an average of 2.5 years

InterventionParticipant (Number)
Ticagrelor 90 mg bd1119
Clopidogrel 75 mg od1140

Net Clinical Benefit (Composite of All-cause Mortality/MI/Ischemic Stroke/ALI/Major Amputation/TIMI Major Bleeding)

Participants with all-cause death, MI, ischemic stroke, ALI, major amputation or Thrombolysis in Myocardial Infarction (TIMI) major bleeding. If no event, censoring occurs at the minimum of (PACD, last endpoint assessment date) (NCT01732822)
Timeframe: From randomization to PACD, an average of 2.5 years

InterventionParticipant (Number)
Ticagrelor 90 mg bd1183
Clopidogrel 75 mg od1199

Net Clinical Benefit (Composite of All-cause Mortality/MI/Ischemic Stroke/Fatal Bleeding/Intracranial Bleeding)

Participants with all-cause death, MI, ischemic stroke, fatal bleeding or intracranial bleeding. If no event, censoring occurs at the minimum of (PACD, last endpoint assessment date) (NCT01732822)
Timeframe: From randomization to PACD, an average of 2.5 years

InterventionParticipant (Number)
Ticagrelor 90 mg bd983
Clopidogrel 75 mg od992

Net Clinical Benefit (Composite of CV Death/MI/Ischemic Stroke/Fatal Bleeding/Intracranial Bleeding)

Participants with CV death, MI, ischemic stroke, fatal bleeding or intracranial bleeding. If no event, censoring occurs at the minimum of (PACD, last endpoint assessment date, non-CV death date) (NCT01732822)
Timeframe: From randomization to PACD, an average of 2.5 years

InterventionParticipant (Number)
Ticagrelor 90 mg bd789
Clopidogrel 75 mg od786

Non-CV Death

Participants with non-CV death. If no event, censoring occurs at the minimum of (PACD, last endpoint assessment date, CV death) (NCT01732822)
Timeframe: From randomization to PACD, an average of 2.5 years

InterventionParticipant (Number)
Ticagrelor 90 mg bd250
Clopidogrel 75 mg od272

PLATO Major Bleeding Events

Participants with PLATO major bleeding event. If no event, censoring occurs at the minimum of (last endpoint assessment date, death date, 7 days after last dose of study drug) (NCT01732822)
Timeframe: From the date of first dose and up to and including 7 days following the date of last dose of study drug

InterventionParticipant (Number)
Ticagrelor 90 mg bd206
Clopidogrel 75 mg od188

Premature Permanent Discontinuation of Study Drug Due to Any Bleeding Event

Participants with a permanent discontinuation of study drug due to any bleeding event. If no event, censoring occurs at the minimum of (last endpoint assessment date, death date, 7 days after last dose of study drug) (NCT01732822)
Timeframe: From the date of first dose and up to and including 7 days following the date of last dose of study drug

InterventionParticipant (Number)
Ticagrelor 90 mg bd168
Clopidogrel 75 mg od112

TIMI Major Bleeding Events

Participants with TIMI major bleeding event. If no event, censoring occurs at the minimum of (last endpoint assessment date, death date, 7 days after last dose of study drug) (NCT01732822)
Timeframe: From the date of first dose and up to and including 7 days following the date of last dose of study drug

InterventionParticipant (Number)
Ticagrelor 90 mg bd113
Clopidogrel 75 mg od109

TIMI Major or Minor Bleeding Events

Participants with TIMI major or minor bleeding event. If no event, censoring occurs at the minimum of (last endpoint assessment date, death date, 7 days after last dose of study drug) (NCT01732822)
Timeframe: From the date of first dose and up to and including 7 days following the date of last dose of study drug

InterventionParticipant (Number)
Ticagrelor 90 mg bd193
Clopidogrel 75 mg od175

Change in ABI/TBI From Baseline

"Change in ankle brachial index (ABI) / toe brachial index (TBI).~Ankle brachial index (ABI) is the ratio of blood pressures from the ankle and arm and is used for diagnosing peripheral arterial occlusive disease (PAOD):~Normal: 1 to 1.29 Borderline: 0.91 to 0.99 Mild PAOD: 0.71 to 0.90 Medium severe PAOD: 0.41 to 0.7 Severe PAOD: <0.4~Toe brachial index (TBI) is the ratio between the toe pressure and the higher brachial pressure, used for diagnosing PAOD when the ABI cannot be used:~Normal: >0.7 Mild: 0.5-0.7 Moderate: 0.35-0.5 Moderate-Severe: <0.35 and toe pressure 40 mmHg Severe: <0.35 and toe pressure < 30 mmHg" (NCT01732822)
Timeframe: From randomization to PACD, an average of 2.5 years

,
InterventionChange in ABI/TBI (Mean)
ABI - 6 months N = 6184(Tica), 6319(Clopi)ABI - End of treatment N = 4951(Tica), 5073(Clopi)TBI - 6 months N = 55(Tica), 48(Clopi)TBI - End of treatment N = 36(Tica), 21(Clopi)
Clopidogrel 75 mg od0.0110.0160.036-0.065
Ticagrelor 90 mg bd0.0160.0220.0500.059

Changes in Fontaine Stage

"Progression of the clinical/symptomatic status of the limb by changes in Fontaine stage.~Stage I - Asymptomatic Stage IIa - Intermittent claudication after more than 200 meters of pain free walking Stage IIb - Intermittent claudication after less than 200 meters of walking Stage III - Rest pain Stage IV - Ischemic ulcers or gangrene" (NCT01732822)
Timeframe: From randomization to PACD, an average of 2.5 years

,,,,,,,,,
InterventionParticipant (Number)
Stage I - End of treatmentStage IIa - End of treatmentStage IIb - End of treatmentStage III - End of treatmentStage IV - End of treatmentMissing - End of treatment
Clopidogrel - Stage I7432305694250
Clopidogrel - Stage IIa7231956311157724
Clopidogrel - Stage IIb1985574502310370
Clopidogrel - Stage III33333823560
Clopidogrel - Stage IV192115121345
Ticagrelor - Stage I7752274577248
Ticagrelor - Stage IIa6831948269247743
Ticagrelor - Stage IIb171560469125403
Ticagrelor - Stage III15413931159
Ticagrelor - Stage IV26281971347

Changes in Rutherford Classification

"Progression of the clinical/symptomatic status of the limb by changes in Rutherford classification.~Category 0 - Asymptomatic Category 1 - Mild claudication Category 2 - Moderate claudication - The distance that delineates mild, moderate and severe claudication is not specified in the Rutherford classification, but is mentioned in the Fontaine classification as 200 meters.~Category 3 - Severe claudication Category 4 - Rest pain Category 5 - Ischemic ulceration not exceeding ulcer of the digits of the foot Category 6 - Severe ischemic ulcers or frank gangrene" (NCT01732822)
Timeframe: From randomization to PACD, an average of 2.5 years

,,,,,,,,,,,
InterventionParticipant (Number)
Category 0 - End of treatmentCategory 1/2 - End of treatmentCategory 3 - End of treatmentCategory 4 - End of treatmentCategory 5 - End of treatmentCategory 6 - End of treatmentMissing - End of treatment
Clopidogrel - Cat 074323056922250
Clopidogrel - Cat 1/272319563111561724
Clopidogrel - Cat 31985574502364370
Clopidogrel - Cat 4333338234160
Clopidogrel - Cat 51318121112034
Clopidogrel - Cat 663311011
Ticagrelor - Cat 077522745752248
Ticagrelor - Cat 31715604691232403
Ticagrelor - Cat 4154139311059
Ticagrelor - Cat 5232313411033
Ticagrelor - Cat 635630214
Ticagrelor - Stage II68319482692443743

Composite of Ischemic Stroke, Myocardial Infarction, Death From Ischemic Vascular Causes, or Major Hemorrhage

Secondary efficacy outcome: Number of participants with ischemic stroke, myocardial infarction, death from ischemic vascular causes, or major hemorrhage (NCT00991029)
Timeframe: Up to 90 days

InterventionParticipants (Count of Participants)
Clopidogrel141
Placebo167

Composite of Ischemic Stroke, Myocardial Infarction, or Death From Ischemic Vascular Causes

Primary efficacy outcome: Number of Participants with Ischemic Stroke, Myocardial Infarction, or Death From Ischemic Vascular Causes (NCT00991029)
Timeframe: Up to 90 days

InterventionParticipants (Count of Participants)
Clopidogrel121
Placebo160

Death From Any Cause

Other safety outcome: Number of Participants with Death from any cause (NCT00991029)
Timeframe: up to 90 days

InterventionParticipants (Count of Participants)
Clopidogrel18
Placebo12

Death From Ischemic Vascular Causes

Secondary efficacy outcome: Number of participants with Death from ischemic vascular causes (NCT00991029)
Timeframe: Up to 90 days

InterventionParticipants (Count of Participants)
Clopidogrel6
Placebo4

Hemorrhagic Stroke

Other safety outcome: Number of participants with Hemorrhagic stroke (NCT00991029)
Timeframe: up to 90 days

InterventionParticipants (Count of Participants)
Clopidogrel5
Placebo3

Ischemic or Hemorrhagic Stroke

Secondary efficacy outcome: Number of participants with Ischemic or hemorrhagic stroke (NCT00991029)
Timeframe: Up to 90 days

InterventionParticipants (Count of Participants)
Clopidogrel116
Placebo156

Ischemic Stroke

Secondary efficacy outcome:Number of participants with Ischemic stroke (NCT00991029)
Timeframe: Up to 90 days

InterventionParticipants (Count of Participants)
Clopidogrel112
Placebo155

Major Hemorrhage

Primary safety outcome: Number of Participants with major hemorrhage (NCT00991029)
Timeframe: Up to 90 days

InterventionParticipants (Count of Participants)
Clopidogrel23
Placebo10

Major Hemorrhage Other Than Intracranial Hemorrhage

Other safety outcome: Number of Participants with Major hemorrhage other than intracranial hemorrhage (NCT00991029)
Timeframe: up to 90 days

InterventionParticipants (Count of Participants)
Clopidogrel17
Placebo7

Minor Hemorrhage

Other safety outcome:Number of Participants with Minor hemorrhage (NCT00991029)
Timeframe: up to 90 days

InterventionParticipants (Count of Participants)
Clopidogrel40
Placebo13

Myocardial Infarction

Secondary efficacy outcome: Number of participants with Myocardial infarction (NCT00991029)
Timeframe: Up to 90 days

InterventionParticipants (Count of Participants)
Clopidogrel10
Placebo7

Other Symptomatic Intracranial Hemorrhage

Other safety outcome: Number of participants with other symptomatic intracranial hemorrhage (NCT00991029)
Timeframe: up to 90 days

InterventionParticipants (Count of Participants)
Clopidogrel2
Placebo0

Symptomatic Intracerebral Hemorrhage

Other safety outcome: Number of participants with Symptomatic intracerebral hemorrhage (NCT00991029)
Timeframe: up to 90 days

InterventionParticipants (Count of Participants)
Clopidogrel2
Placebo2

Event-free Survival Rate

"Event-free survival is defined as freedom from the major adverse events of death, target lesion revascularization, target limb ischemia requiring surgical intervention (bypass or amputation of toe, foot or leg), surgical repair of the target vessel (e.g., dissection requiring surgery), and from worsening of the Rutherford classification by 2 classes or to class 5 or 6.~Participant flow is based on initial randomization of Zilver PTX or PTA (Percutaneous balloon angioplasty), and Event-free survival is based on Per-Protocol analysis where only patients who were treated according to their initial randomization are counted." (NCT00120406)
Timeframe: 12 months

InterventionPercentage of participants (Number)
Zilver PTX90.4
PTA (Control)83.9

Primary Patency

Primary patency is defined as a Peak systolic velocity (PSV) ratio < 2.0 or angiographic percent diameter stenosis < 50%. (NCT00120406)
Timeframe: 12 months

InterventionPercentage of participants (Number)
Zilver PTX82.7
PTA (Control)32.7

Number of Participants With New MRI (Magnetic Resonance Image) Lesions on Follow-up MRI

number of patients with new ischemic lesions on FLAIR (Fluid attenuation inversion recovery) images of follow-up MRI, which were determined by slice to slice comparison with baseline MRI. (NCT00130039)
Timeframe: 7 months after treatment

Interventionpariticipants (Number)
Cilostazol34
Clopidogrel23

Number of Participants With Overall Cardiovascular Events

including nonfatal stroke, nonfatal myocardial infarction and vascular death. (NCT00130039)
Timeframe: upto 7 months after randomization

Interventionparticipants (Number)
Cilostazol15
Clopidogrel10

Number of Participants With Progression of Symptomatic Intracranial Stenosis

"Blind reviewers classified the presence and severity of stenosis on middle cerebral arteries and basilar artery on magnetic resonance angiogram (MRA) into 5 grades; normal, mild, moderate, severe and occlusion. Progression was defined as worsening of stenosis by 1 or more grades on final MRA as compared with the baseline MRA.~The progression of symptomatic stenosis is defined as 1 or more grade worsening of the stenosis on the symptomatic artery on MRA." (NCT00130039)
Timeframe: 7 months after treatment

Interventionparticipants (Number)
Cilostazol20
Clopidogrel32

Number of Participants With Stroke Events

including nonfatal ischemic stroke, nonfatal hemorrhagic stroke and fatal stroke (NCT00130039)
Timeframe: upto 7 months after randomization

Interventionparticipants (Number)
Cilostazol11
Clopidogrel7

Number of Patients With Ipsilateral Ischemic Stroke Rate

ischemic stroke event which occured in the vascular territory of initial symptomatic stenosis (NCT00130039)
Timeframe: upto 7 months after randomization

Interventionparticipants (Number)
Cilostazol9
Clopidogrel5

Numbers of Fatal or Major Bleeding Complications

life-threatening or fatal bleeding was defined as any fatal bleeding event, a drop in hemoglobin of ≥ 50g/L, or significant hypotension with need for inotropic agents, symptomatic intracranial hemorrhage, or transfusion of ≥ 4 units of red-blood cells or equivalent amount of whole blood. Major bleeding was defined as significantly disabling bleedings, intraocular bleeding leading to significant visual loss, or bleeding requiring transfusion of ≤ 3 units of red-blood cells or equivalent amount of whole blood (NCT00130039)
Timeframe: upto 7 months after randomization

Interventionevents (Number)
Cilostazol2
Clopidogrel6

Incidence of Major Adverse Coronary Events Within One Year Following Surgery

(NCT00228423)
Timeframe: 1 year

InterventionParticipants (Count of Participants)
75mg Clopidogrel4
Placebo5

Incidence of Major Bleeding Events Within One Year Following Surgery

(NCT00228423)
Timeframe: 1 year

InterventionParticipants (Count of Participants)
75mg Clopidogrel1
Placebo0

Vein Graft Angiographic Patency

Postoperative angiogram 12 months post-CABG (NCT00228423)
Timeframe: One year following surgery

Interventionpercentage (Number)
75mg Clopidogrel94.3
Placebo93.2

Vein Graft Intimal Area

IVUS imaging 12 months post-CABG, and the average intimal area in the proximal 40 mm of one vein graft per patient will be assessed (NCT00228423)
Timeframe: One year following surgery

Interventionmm (Mean)
75mg Clopidogrel4.1
Placebo4.5

Reviews

24 reviews available for ticlopidine and Ischemia

ArticleYear
Continuation versus discontinuation of antiplatelet therapy for bleeding and ischaemic events in adults undergoing non-cardiac surgery.
    The Cochrane database of systematic reviews, 2018, 07-18, Volume: 7

    Topics: Adult; Aspirin; Cause of Death; Clopidogrel; Elective Surgical Procedures; Hemorrhage; Humans; Ische

2018
Suboptimal response to clopidogrel: a genetic risk factor for recurrent ischaemic stroke.
    Journal of clinical neuroscience : official journal of the Neurosurgical Society of Australasia, 2013, Volume: 20, Issue:6

    Topics: Aryl Hydrocarbon Hydroxylases; Clopidogrel; Cytochrome P-450 CYP2C19; Dose-Response Relationship, Dr

2013
Antiplatelet therapy in critical limb ischemia: update on clopidogrel and cilostazol.
    The Journal of cardiovascular surgery, 2014, Volume: 55, Issue:5

    Topics: Cilostazol; Clopidogrel; Combined Modality Therapy; Critical Illness; Drug Therapy, Combination; End

2014
Systematic reviews and meta-analyses for more profitable strategies in peripheral artery disease.
    Annals of medicine, 2014, Volume: 46, Issue:7

    Topics: Adenosine; Aspirin; Asymptomatic Diseases; Cilostazol; Clopidogrel; Fibrinolytic Agents; Humans; Int

2014
Clinical implications of aspirin resistance.
    Thrombosis and haemostasis, 2008, Volume: 100, Issue:3

    Topics: Aspirin; Atherosclerosis; Clinical Trials as Topic; Clopidogrel; Coronary Disease; Drug Resistance;

2008
The rationale for and comparisons of different antiplatelet treatments in acute coronary syndrome.
    Journal of interventional cardiology, 2008, Volume: 21 Suppl 1

    Topics: Acute Coronary Syndrome; Aspirin; Blood Coagulation; Blood Platelets; Clopidogrel; Drug Therapy, Com

2008
Monitoring platelet function to reduce the risk of ischemic and bleeding complications.
    The American journal of cardiology, 2009, Feb-02, Volume: 103, Issue:3 Suppl

    Topics: Acute Coronary Syndrome; Angioplasty, Balloon, Coronary; Aspirin; Blood Platelets; Clopidogrel; Hemo

2009
Combination antiplatelet therapy in patients with peripheral arterial disease: is the best therapy aspirin, clopidogrel, or both?
    Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions, 2009, Jul-01, Volume: 74 Suppl 1

    Topics: Aspirin; Atherosclerosis; Clopidogrel; Drug Resistance; Drug Therapy, Combination; Evidence-Based Me

2009
Aspirin and clopidogrel: efficacy and resistance in diabetes mellitus.
    Best practice & research. Clinical endocrinology & metabolism, 2009, Volume: 23, Issue:3

    Topics: Aspirin; Clopidogrel; Diabetes Mellitus; Drug Resistance; Endothelium, Vascular; Humans; Ischemia; O

2009
Platelet function testing and implications for clinical practice.
    Journal of cardiovascular pharmacology and therapeutics, 2009, Volume: 14, Issue:3

    Topics: Aspirin; Blood Platelets; Clopidogrel; Drug Resistance; Hemorrhage; Hemostasis; Humans; Ischemia; Pl

2009
[Medicinal therapy for interventional surgery of the peripheral vascular system].
    Der Radiologe, 2010, Volume: 50, Issue:1

    Topics: Administration, Oral; Anticoagulants; Arterial Occlusive Diseases; Aspirin; Clopidogrel; Drug Therap

2010
Antiplatelet therapy prasugrel: a novel platelet ADP P2Y12 receptor antagonist.
    Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis, 2010, Volume: 16, Issue:2

    Topics: Acute Coronary Syndrome; Angioplasty, Balloon, Coronary; Aspirin; Clinical Trials, Phase III as Topi

2010
Ischaemic and bleeding complications with new, compared to standard, ADP-antagonist regimens in acute coronary syndromes: a meta-analysis of randomized trials.
    QJM : monthly journal of the Association of Physicians, 2011, Volume: 104, Issue:7

    Topics: Acute Coronary Syndrome; Adenosine; Administration, Oral; Clopidogrel; Hemorrhage; Humans; Ischemia;

2011
Antiplatelets in secondary stroke prevention: should clopidogrel be the first choice?
    Postgraduate medical journal, 2012, Volume: 88, Issue:1035

    Topics: Aspirin; Clopidogrel; Dipyridamole; Humans; Ischemia; Ischemic Attack, Transient; Platelet Aggregati

2012
Primary prevention of ischaemic cardiovascular disorders with antiplatelet agents.
    Handbook of experimental pharmacology, 2012, Issue:210

    Topics: Aspirin; Cardiovascular Diseases; Clinical Trials as Topic; Clopidogrel; Humans; Ischemia; Myocardia

2012
Comparing newer oral anti-platelets prasugrel and ticagrelor in reduction of ischemic events-evidence from a network meta-analysis.
    Journal of thrombosis and thrombolysis, 2013, Volume: 36, Issue:3

    Topics: Adenosine; Clopidogrel; Hemorrhage; Humans; Ischemia; Piperazines; Platelet Aggregation Inhibitors;

2013
Antiplatelet drug resistance and variability in response: the role of antiplatelet therapy monitoring.
    Current pharmaceutical design, 2013, Volume: 19, Issue:21

    Topics: Aspirin; Clopidogrel; Coronary Artery Disease; Cost Savings; Drug Monitoring; Drug Resistance; Drug

2013
Antiplatelet agents in atherothrombotic diseases.
    Hospital medicine (London, England : 1998), 2004, Volume: 65, Issue:2

    Topics: Arteriosclerosis; Aspirin; Clopidogrel; Dipyridamole; Humans; Ischemia; Platelet Aggregation Inhibit

2004
Antithrombotic therapy in peripheral arterial occlusive disease: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy.
    Chest, 2004, Volume: 126, Issue:3 Suppl

    Topics: Arterial Occlusive Diseases; Aspirin; Cilostazol; Clopidogrel; Contraindications; Evidence-Based Med

2004
Clinical effectiveness and cost-effectiveness of clopidogrel and modified-release dipyridamole in the secondary prevention of occlusive vascular events: a systematic review and economic evaluation.
    Health technology assessment (Winchester, England), 2004, Volume: 8, Issue:38

    Topics: Aspirin; Clopidogrel; Cost-Benefit Analysis; Delayed-Action Preparations; Diarrhea; Dipyridamole; Dr

2004
Role of antiplatelet agents in the primary and secondary prevention of atherothrombotic events in high risk-patients.
    Southern medical journal, 2008, Volume: 101, Issue:3

    Topics: Aspirin; Atherosclerosis; Clinical Trials as Topic; Clopidogrel; Dose-Response Relationship, Drug; D

2008
Aspirin, clopidogrel, and warfarin: is the combination appropriate and effective or inappropriate and too dangerous?
    The Annals of pharmacotherapy, 2008, Volume: 42, Issue:6

    Topics: Anticoagulants; Aspirin; Clinical Trials as Topic; Clopidogrel; Drug Interactions; Drug Therapy, Com

2008
The results of CAPRIE, IST and CAST. Clopidogrel vs. Aspirin in Patients at Risk of Ischaemic Events. International Stroke Trial. Chinese Acute Stroke Trial.
    Thrombosis research, 1998, Sep-15, Volume: 92, Issue:1 Suppl 1

    Topics: Aspirin; Cerebrovascular Disorders; Clopidogrel; Double-Blind Method; Humans; Ischemia; Myocardial I

1998
Adjuvant medical therapy in peripheral bypass surgery.
    The British journal of surgery, 1999, Volume: 86, Issue:8

    Topics: Alprostadil; Anticoagulants; Aspirin; Chemotherapy, Adjuvant; Clinical Trials as Topic; Dextrans; Do

1999

Trials

22 trials available for ticlopidine and Ischemia

ArticleYear
Outcomes of Patients with Critical Limb Ischaemia in the EUCLID Trial.
    European journal of vascular and endovascular surgery : the official journal of the European Society for Vascular Surgery, 2018, Volume: 55, Issue:1

    Topics: Adenosine; Aged; Clopidogrel; Female; Hospitalization; Humans; Hypertension; Incidence; Ischemia; Ka

2018
Antiplatelet therapy with aspirin, clopidogrel, and dipyridamole versus clopidogrel alone or aspirin and dipyridamole in patients with acute cerebral ischaemia (TARDIS): a randomised, open-label, phase 3 superiority trial.
    Lancet (London, England), 2018, 03-03, Volume: 391, Issue:10123

    Topics: Acute Disease; Aged; Aspirin; Brain Ischemia; Clopidogrel; Denmark; Dipyridamole; Drug Therapy, Comb

2018
Clopidogrel and Aspirin in Acute Ischemic Stroke and High-Risk TIA.
    The New England journal of medicine, 2018, Jul-19, Volume: 379, Issue:3

    Topics: Aged; Aspirin; Brain Ischemia; Clopidogrel; Double-Blind Method; Drug Therapy, Combination; Female;

2018
Clopidogrel and Aspirin in Acute Ischemic Stroke and High-Risk TIA.
    The New England journal of medicine, 2018, Jul-19, Volume: 379, Issue:3

    Topics: Aged; Aspirin; Brain Ischemia; Clopidogrel; Double-Blind Method; Drug Therapy, Combination; Female;

2018
Clopidogrel and Aspirin in Acute Ischemic Stroke and High-Risk TIA.
    The New England journal of medicine, 2018, Jul-19, Volume: 379, Issue:3

    Topics: Aged; Aspirin; Brain Ischemia; Clopidogrel; Double-Blind Method; Drug Therapy, Combination; Female;

2018
Clopidogrel and Aspirin in Acute Ischemic Stroke and High-Risk TIA.
    The New England journal of medicine, 2018, Jul-19, Volume: 379, Issue:3

    Topics: Aged; Aspirin; Brain Ischemia; Clopidogrel; Double-Blind Method; Drug Therapy, Combination; Female;

2018
Clopidogrel and Aspirin in Acute Ischemic Stroke and High-Risk TIA.
    The New England journal of medicine, 2018, Jul-19, Volume: 379, Issue:3

    Topics: Aged; Aspirin; Brain Ischemia; Clopidogrel; Double-Blind Method; Drug Therapy, Combination; Female;

2018
Clopidogrel and Aspirin in Acute Ischemic Stroke and High-Risk TIA.
    The New England journal of medicine, 2018, Jul-19, Volume: 379, Issue:3

    Topics: Aged; Aspirin; Brain Ischemia; Clopidogrel; Double-Blind Method; Drug Therapy, Combination; Female;

2018
Clopidogrel and Aspirin in Acute Ischemic Stroke and High-Risk TIA.
    The New England journal of medicine, 2018, Jul-19, Volume: 379, Issue:3

    Topics: Aged; Aspirin; Brain Ischemia; Clopidogrel; Double-Blind Method; Drug Therapy, Combination; Female;

2018
Clopidogrel and Aspirin in Acute Ischemic Stroke and High-Risk TIA.
    The New England journal of medicine, 2018, Jul-19, Volume: 379, Issue:3

    Topics: Aged; Aspirin; Brain Ischemia; Clopidogrel; Double-Blind Method; Drug Therapy, Combination; Female;

2018
Clopidogrel and Aspirin in Acute Ischemic Stroke and High-Risk TIA.
    The New England journal of medicine, 2018, Jul-19, Volume: 379, Issue:3

    Topics: Aged; Aspirin; Brain Ischemia; Clopidogrel; Double-Blind Method; Drug Therapy, Combination; Female;

2018
Clopidogrel and Aspirin in Acute Ischemic Stroke and High-Risk TIA.
    The New England journal of medicine, 2018, Jul-19, Volume: 379, Issue:3

    Topics: Aged; Aspirin; Brain Ischemia; Clopidogrel; Double-Blind Method; Drug Therapy, Combination; Female;

2018
Clopidogrel and Aspirin in Acute Ischemic Stroke and High-Risk TIA.
    The New England journal of medicine, 2018, Jul-19, Volume: 379, Issue:3

    Topics: Aged; Aspirin; Brain Ischemia; Clopidogrel; Double-Blind Method; Drug Therapy, Combination; Female;

2018
Clopidogrel and Aspirin in Acute Ischemic Stroke and High-Risk TIA.
    The New England journal of medicine, 2018, Jul-19, Volume: 379, Issue:3

    Topics: Aged; Aspirin; Brain Ischemia; Clopidogrel; Double-Blind Method; Drug Therapy, Combination; Female;

2018
Clopidogrel and Aspirin in Acute Ischemic Stroke and High-Risk TIA.
    The New England journal of medicine, 2018, Jul-19, Volume: 379, Issue:3

    Topics: Aged; Aspirin; Brain Ischemia; Clopidogrel; Double-Blind Method; Drug Therapy, Combination; Female;

2018
Clopidogrel and Aspirin in Acute Ischemic Stroke and High-Risk TIA.
    The New England journal of medicine, 2018, Jul-19, Volume: 379, Issue:3

    Topics: Aged; Aspirin; Brain Ischemia; Clopidogrel; Double-Blind Method; Drug Therapy, Combination; Female;

2018
Clopidogrel and Aspirin in Acute Ischemic Stroke and High-Risk TIA.
    The New England journal of medicine, 2018, Jul-19, Volume: 379, Issue:3

    Topics: Aged; Aspirin; Brain Ischemia; Clopidogrel; Double-Blind Method; Drug Therapy, Combination; Female;

2018
Clopidogrel and Aspirin in Acute Ischemic Stroke and High-Risk TIA.
    The New England journal of medicine, 2018, Jul-19, Volume: 379, Issue:3

    Topics: Aged; Aspirin; Brain Ischemia; Clopidogrel; Double-Blind Method; Drug Therapy, Combination; Female;

2018
Clopidogrel and Aspirin in Acute Ischemic Stroke and High-Risk TIA.
    The New England journal of medicine, 2018, Jul-19, Volume: 379, Issue:3

    Topics: Aged; Aspirin; Brain Ischemia; Clopidogrel; Double-Blind Method; Drug Therapy, Combination; Female;

2018
Clopidogrel and Aspirin in Acute Ischemic Stroke and High-Risk TIA.
    The New England journal of medicine, 2018, Jul-19, Volume: 379, Issue:3

    Topics: Aged; Aspirin; Brain Ischemia; Clopidogrel; Double-Blind Method; Drug Therapy, Combination; Female;

2018
Clopidogrel and Aspirin in Acute Ischemic Stroke and High-Risk TIA.
    The New England journal of medicine, 2018, Jul-19, Volume: 379, Issue:3

    Topics: Aged; Aspirin; Brain Ischemia; Clopidogrel; Double-Blind Method; Drug Therapy, Combination; Female;

2018
Clopidogrel and Aspirin in Acute Ischemic Stroke and High-Risk TIA.
    The New England journal of medicine, 2018, Jul-19, Volume: 379, Issue:3

    Topics: Aged; Aspirin; Brain Ischemia; Clopidogrel; Double-Blind Method; Drug Therapy, Combination; Female;

2018
Clopidogrel and Aspirin in Acute Ischemic Stroke and High-Risk TIA.
    The New England journal of medicine, 2018, Jul-19, Volume: 379, Issue:3

    Topics: Aged; Aspirin; Brain Ischemia; Clopidogrel; Double-Blind Method; Drug Therapy, Combination; Female;

2018
Clopidogrel and Aspirin in Acute Ischemic Stroke and High-Risk TIA.
    The New England journal of medicine, 2018, Jul-19, Volume: 379, Issue:3

    Topics: Aged; Aspirin; Brain Ischemia; Clopidogrel; Double-Blind Method; Drug Therapy, Combination; Female;

2018
Clopidogrel and Aspirin in Acute Ischemic Stroke and High-Risk TIA.
    The New England journal of medicine, 2018, Jul-19, Volume: 379, Issue:3

    Topics: Aged; Aspirin; Brain Ischemia; Clopidogrel; Double-Blind Method; Drug Therapy, Combination; Female;

2018
Clopidogrel and Aspirin in Acute Ischemic Stroke and High-Risk TIA.
    The New England journal of medicine, 2018, Jul-19, Volume: 379, Issue:3

    Topics: Aged; Aspirin; Brain Ischemia; Clopidogrel; Double-Blind Method; Drug Therapy, Combination; Female;

2018
Clopidogrel and Aspirin in Acute Ischemic Stroke and High-Risk TIA.
    The New England journal of medicine, 2018, Jul-19, Volume: 379, Issue:3

    Topics: Aged; Aspirin; Brain Ischemia; Clopidogrel; Double-Blind Method; Drug Therapy, Combination; Female;

2018
Clopidogrel and Aspirin in Acute Ischemic Stroke and High-Risk TIA.
    The New England journal of medicine, 2018, Jul-19, Volume: 379, Issue:3

    Topics: Aged; Aspirin; Brain Ischemia; Clopidogrel; Double-Blind Method; Drug Therapy, Combination; Female;

2018
Clopidogrel and Aspirin in Acute Ischemic Stroke and High-Risk TIA.
    The New England journal of medicine, 2018, Jul-19, Volume: 379, Issue:3

    Topics: Aged; Aspirin; Brain Ischemia; Clopidogrel; Double-Blind Method; Drug Therapy, Combination; Female;

2018
Clopidogrel and Aspirin in Acute Ischemic Stroke and High-Risk TIA.
    The New England journal of medicine, 2018, Jul-19, Volume: 379, Issue:3

    Topics: Aged; Aspirin; Brain Ischemia; Clopidogrel; Double-Blind Method; Drug Therapy, Combination; Female;

2018
Clopidogrel and Aspirin in Acute Ischemic Stroke and High-Risk TIA.
    The New England journal of medicine, 2018, Jul-19, Volume: 379, Issue:3

    Topics: Aged; Aspirin; Brain Ischemia; Clopidogrel; Double-Blind Method; Drug Therapy, Combination; Female;

2018
Clopidogrel and Aspirin in Acute Ischemic Stroke and High-Risk TIA.
    The New England journal of medicine, 2018, Jul-19, Volume: 379, Issue:3

    Topics: Aged; Aspirin; Brain Ischemia; Clopidogrel; Double-Blind Method; Drug Therapy, Combination; Female;

2018
Clopidogrel and Aspirin in Acute Ischemic Stroke and High-Risk TIA.
    The New England journal of medicine, 2018, Jul-19, Volume: 379, Issue:3

    Topics: Aged; Aspirin; Brain Ischemia; Clopidogrel; Double-Blind Method; Drug Therapy, Combination; Female;

2018
Clopidogrel and Aspirin in Acute Ischemic Stroke and High-Risk TIA.
    The New England journal of medicine, 2018, Jul-19, Volume: 379, Issue:3

    Topics: Aged; Aspirin; Brain Ischemia; Clopidogrel; Double-Blind Method; Drug Therapy, Combination; Female;

2018
Clopidogrel and Aspirin in Acute Ischemic Stroke and High-Risk TIA.
    The New England journal of medicine, 2018, Jul-19, Volume: 379, Issue:3

    Topics: Aged; Aspirin; Brain Ischemia; Clopidogrel; Double-Blind Method; Drug Therapy, Combination; Female;

2018
Clopidogrel and Aspirin in Acute Ischemic Stroke and High-Risk TIA.
    The New England journal of medicine, 2018, Jul-19, Volume: 379, Issue:3

    Topics: Aged; Aspirin; Brain Ischemia; Clopidogrel; Double-Blind Method; Drug Therapy, Combination; Female;

2018
Clopidogrel and Aspirin in Acute Ischemic Stroke and High-Risk TIA.
    The New England journal of medicine, 2018, Jul-19, Volume: 379, Issue:3

    Topics: Aged; Aspirin; Brain Ischemia; Clopidogrel; Double-Blind Method; Drug Therapy, Combination; Female;

2018
Clopidogrel and Aspirin in Acute Ischemic Stroke and High-Risk TIA.
    The New England journal of medicine, 2018, Jul-19, Volume: 379, Issue:3

    Topics: Aged; Aspirin; Brain Ischemia; Clopidogrel; Double-Blind Method; Drug Therapy, Combination; Female;

2018
A prospective randomized controlled clinical trial on clopidogrel combined with warfarin versus clopidogrel alone in the prevention of restenosis after endovascular treatment of the femoropopliteal artery.
    Annals of vascular surgery, 2013, Volume: 27, Issue:5

    Topics: Aged; Anticoagulants; Clopidogrel; Constriction, Pathologic; Drug Therapy, Combination; Endovascular

2013
Durable Clinical Effectiveness With Paclitaxel-Eluting Stents in the Femoropopliteal Artery: 5-Year Results of the Zilver PTX Randomized Trial.
    Circulation, 2016, Apr-12, Volume: 133, Issue:15

    Topics: Adult; Aged; Angioplasty; Anticoagulants; Arterial Occlusive Diseases; Aspirin; Clopidogrel; Combine

2016
Durable Clinical Effectiveness With Paclitaxel-Eluting Stents in the Femoropopliteal Artery: 5-Year Results of the Zilver PTX Randomized Trial.
    Circulation, 2016, Apr-12, Volume: 133, Issue:15

    Topics: Adult; Aged; Angioplasty; Anticoagulants; Arterial Occlusive Diseases; Aspirin; Clopidogrel; Combine

2016
Durable Clinical Effectiveness With Paclitaxel-Eluting Stents in the Femoropopliteal Artery: 5-Year Results of the Zilver PTX Randomized Trial.
    Circulation, 2016, Apr-12, Volume: 133, Issue:15

    Topics: Adult; Aged; Angioplasty; Anticoagulants; Arterial Occlusive Diseases; Aspirin; Clopidogrel; Combine

2016
Durable Clinical Effectiveness With Paclitaxel-Eluting Stents in the Femoropopliteal Artery: 5-Year Results of the Zilver PTX Randomized Trial.
    Circulation, 2016, Apr-12, Volume: 133, Issue:15

    Topics: Adult; Aged; Angioplasty; Anticoagulants; Arterial Occlusive Diseases; Aspirin; Clopidogrel; Combine

2016
Impact of genetic polymorphisms related to clopidogrel or acetylsalicylic acid pharmacology on clinical outcome in Chinese patients with symptomatic extracranial or intracranial stenosis.
    European journal of clinical pharmacology, 2016, Volume: 72, Issue:10

    Topics: Aged; Asian People; Aspirin; Carboxylic Ester Hydrolases; Clopidogrel; Constriction, Pathologic; Cyt

2016
Ticagrelor versus Clopidogrel in Symptomatic Peripheral Artery Disease.
    The New England journal of medicine, 2017, 01-05, Volume: 376, Issue:1

    Topics: Adenosine; Aged; Cardiovascular Diseases; Clopidogrel; Double-Blind Method; Female; Hemorrhage; Huma

2017
Gastrointestinal bleeding in patients with acute coronary syndromes: incidence, predictors, and clinical implications: analysis from the ACUITY (Acute Catheterization and Urgent Intervention Triage Strategy) trial.
    Journal of the American College of Cardiology, 2009, Sep-29, Volume: 54, Issue:14

    Topics: Acute Coronary Syndrome; Age Factors; Aged; Angioplasty, Balloon, Coronary; Anticoagulants; Clopidog

2009
Ticagrelor, a new antiplatelet agent, for prevention of ischemic events in patients with coronary artery disease.
    Current neurology and neuroscience reports, 2010, Volume: 10, Issue:1

    Topics: Adenosine; Clopidogrel; Coronary Artery Disease; Double-Blind Method; Drug Administration Schedule;

2010
Randomized controlled trial of dual antiplatelet therapy in patients undergoing surgery for critical limb ischemia.
    Annals of surgery, 2010, Volume: 252, Issue:1

    Topics: Aged; Amputation, Surgical; Aspirin; Clopidogrel; Double-Blind Method; Female; Flow Cytometry; Hemor

2010
Cytochrome 2C19 polymorphism and response to adjunctive cilostazol versus high maintenance-dose clopidogrel in patients undergoing percutaneous coronary intervention.
    Circulation. Cardiovascular interventions, 2010, Volume: 3, Issue:5

    Topics: Adenosine Diphosphate; Angioplasty, Balloon, Coronary; Aryl Hydrocarbon Hydroxylases; Blood Platelet

2010
Efficacy and safety of combination antiplatelet therapies in patients with symptomatic intracranial atherosclerotic stenosis.
    Stroke, 2011, Volume: 42, Issue:10

    Topics: Aged; Aged, 80 and over; Cilostazol; Clopidogrel; Constriction, Pathologic; Disease Progression; Dou

2011
The relationship between CYP2C19 polymorphisms and ischaemic and bleeding outcomes in stable outpatients: the CHARISMA genetics study.
    European heart journal, 2012, Volume: 33, Issue:17

    Topics: Aryl Hydrocarbon Hydroxylases; Atherosclerosis; Clopidogrel; Cytochrome P-450 CYP2C19; Female; Genot

2012
Increased local cytokine production at culprit superficial femoral artery plaques.
    Journal of thrombosis and thrombolysis, 2013, Volume: 36, Issue:3

    Topics: Aspirin; CD40 Ligand; Clopidogrel; Constriction, Pathologic; Female; Femoral Artery; Humans; Hydroxy

2013
A global view of atherothrombosis: baseline characteristics in the Clopidogrel for High Atherothrombotic Risk and Ischemic Stabilization, Management, and Avoidance (CHARISMA) trial.
    American heart journal, 2005, Volume: 150, Issue:3

    Topics: Adult; Aged; Aged, 80 and over; Brain Ischemia; Cardiovascular Diseases; Clopidogrel; Coronary Disea

2005
Therapeutic effect of ticlopidine for ischemic leg ulcers.
    Agents and actions. Supplements, 1984, Volume: 15

    Topics: Anticoagulants; Arterial Occlusive Diseases; Clinical Trials as Topic; Female; Humans; Ischemia; Leg

1984
Therapeutic effect of ticlopidine, a new inhibitor of platelet aggregation, on chronic arterial occlusive diseases, a double-blind study versus placebo.
    Angiology, 1982, Volume: 33, Issue:6

    Topics: Arterial Occlusive Diseases; Arteriosclerosis; Chronic Disease; Clinical Trials as Topic; Double-Bli

1982
The results of CAPRIE, IST and CAST. Clopidogrel vs. Aspirin in Patients at Risk of Ischaemic Events. International Stroke Trial. Chinese Acute Stroke Trial.
    Thrombosis research, 1998, Sep-15, Volume: 92, Issue:1 Suppl 1

    Topics: Aspirin; Cerebrovascular Disorders; Clopidogrel; Double-Blind Method; Humans; Ischemia; Myocardial I

1998
[The drug prevention of postoperative thromboses in patients with critical lower limb ischemia].
    Likars'ka sprava, 1999, Issue:5

    Topics: Anticoagulants; Aspirin; Critical Illness; Humans; Ischemia; Leg; Nadroparin; Platelet Aggregation I

1999
Reduction in the need for hospitalization for recurrent ischemic events and bleeding with clopidogrel instead of aspirin. CAPRIE investigators.
    American heart journal, 2000, Volume: 140, Issue:1

    Topics: Aspirin; Brain Ischemia; Cause of Death; Clopidogrel; Confidence Intervals; Double-Blind Method; Fem

2000
Superiority of clopidogrel versus aspirin in patients with prior cardiac surgery.
    Circulation, 2001, Jan-23, Volume: 103, Issue:3

    Topics: Aspirin; Cardiac Surgical Procedures; Clopidogrel; Double-Blind Method; Female; Hospitalization; Hum

2001
[Application of preparation endotelon in complex treatment of chronic arterial insufficiency of lower extremities].
    Klinichna khirurhiia, 2000, Issue:10

    Topics: Anti-Inflammatory Agents, Non-Steroidal; Antioxidants; Arterial Occlusive Diseases; Aspirin; Biflavo

2000

Other Studies

47 other studies available for ticlopidine and Ischemia

ArticleYear
Antiplatelet response to clopidogrel is associated with a haplotype in CYP2C19 gene in Pakistani patients.
    Scientific reports, 2022, 04-13, Volume: 12, Issue:1

    Topics: Clopidogrel; Cytochrome P-450 CYP2C19; Genotype; Haplotypes; Humans; Ischemia; Pakistan; Platelet Ag

2022
Previous hypertensive hemorrhage increases the risk for bleeding and ischemia for PCI patients on dual antiplatelet therapy.
    Neurological research, 2017, Volume: 39, Issue:6

    Topics: Adult; Aged; Aged, 80 and over; Aspirin; Case-Control Studies; Clopidogrel; Drug Therapy, Combinatio

2017
Gender-related differences in antiplatelet treatment patterns and outcome: Insights from the GReekAntiPlatElet Registry.
    Cardiovascular therapeutics, 2017, Volume: 35, Issue:4

    Topics: Acute Coronary Syndrome; Aged; Cardiovascular Diseases; Clopidogrel; Cohort Studies; Female; Greece;

2017
The association between clopidogrel and 2-oxo-clopidogrel plasma levels and the long-term clinical outcome after acute myocardial infarction
.
    International journal of clinical pharmacology and therapeutics, 2019, Volume: 57, Issue:2

    Topics: Clopidogrel; Humans; Ischemia; Myocardial Infarction; Percutaneous Coronary Intervention; Platelet A

2019
Platelet antiaggregation therapy and subinguinal endovascular revascularization.
    Annals of vascular surgery, 2013, Volume: 27, Issue:5

    Topics: Aged; Aged, 80 and over; Clopidogrel; Endovascular Procedures; Humans; Ischemia; Lower Extremity; Me

2013
Why have studies of tailored anti-platelet therapy failed so far?
    Thrombosis and haemostasis, 2013, Volume: 110, Issue:4

    Topics: Angioplasty, Balloon, Coronary; Cardiovascular Diseases; Clopidogrel; Drug Resistance; Humans; Ische

2013
Near-real-time monitoring of new drugs: an application comparing prasugrel versus clopidogrel.
    Drug safety, 2014, Volume: 37, Issue:3

    Topics: Aged; Clopidogrel; Cohort Studies; Databases, Factual; Electronic Health Records; Female; Hemorrhage

2014
Levels and values of lipoprotein-associated phospholipase A2, galectin-3, RhoA/ROCK, and endothelial progenitor cells in critical limb ischemia: pharmaco-therapeutic role of cilostazol and clopidogrel combination therapy.
    Journal of translational medicine, 2014, Apr-17, Volume: 12

    Topics: 1-Alkyl-2-acetylglycerophosphocholine Esterase; Aged; Base Sequence; Cilostazol; Clopidogrel; DNA Pr

2014
Statistical Perspectives on Subgroup Analysis: Testing for Heterogeneity and Evaluating Error Rate for the Complementary Subgroup.
    Journal of biopharmaceutical statistics, 2015, Volume: 25, Issue:6

    Topics: Algorithms; Antibiotics, Antineoplastic; Antineoplastic Agents; Aspirin; Clinical Trials as Topic; C

2015
High on-treatment platelet reactivity in transcatheter aortic valve implantation patients.
    European journal of pharmacology, 2015, Mar-15, Volume: 751

    Topics: Aged; Aspirin; Blood Platelets; Clopidogrel; Female; Humans; Ischemia; Male; Platelet Aggregation In

2015
Response to dual antiplatelet therapy in patients with peripheral artery occlusive disease suffering from critical limb ischemia.
    Clinical laboratory, 2014, Volume: 60, Issue:10

    Topics: Aged; Aged, 80 and over; Area Under Curve; Aspirin; Clopidogrel; Critical Illness; Drug Resistance;

2014
Diversity of platelet function and genetic polymorphism in clopidogrel-treated Chinese patients.
    Genetics and molecular research : GMR, 2015, Feb-13, Volume: 14, Issue:1

    Topics: Adenosine Diphosphate; Adult; Aged; Alleles; Blood Coagulation; Blood Platelets; China; Clopidogrel;

2015
Association of dual-antiplatelet therapy with reduced major adverse cardiovascular events in patients with symptomatic peripheral arterial disease.
    Journal of vascular surgery, 2015, Volume: 62, Issue:1

    Topics: Adult; Aged; Aged, 80 and over; Amputation, Surgical; Aspirin; California; Cardiovascular Diseases;

2015
Platelet reactivity in MitraClip patients.
    Vascular pharmacology, 2016, Volume: 77

    Topics: Aspirin; Clopidogrel; Cohort Studies; Heart Valve Prosthesis Implantation; Hemorrhage; Ischemia; Mit

2016
Association of Cytochrome P450 Genetic Variants with Clopidogrel Resistance and Outcomes in Acute Ischemic Stroke.
    Journal of atherosclerosis and thrombosis, 2016, Oct-01, Volume: 23, Issue:10

    Topics: Aged; Clopidogrel; Cytochrome P-450 CYP2C19; Cytochrome P-450 CYP3A; Female; Humans; Ischemia; Male;

2016
Dual Antiplatelet Therapy in the Prevention of Recurrent Ischemic Events.
    Journal of the American College of Cardiology, 2016, 06-14, Volume: 67, Issue:23

    Topics: Aspirin; Brain Ischemia; Drug Therapy, Combination; Humans; Ischemia; Platelet Aggregation Inhibitor

2016
Impact of different antithrombotics on the microcirculation and viability of perforator-based ischaemic skin flaps in a small animal model.
    Scientific reports, 2016, 10-21, Volume: 6

    Topics: Animals; Aspirin; Clopidogrel; Disease Models, Animal; Fibrinolytic Agents; Graft Survival; Heparin;

2016
Editor's Choice - Dual Antiplatelet Therapy Improves Outcome in Diabetic Patients Undergoing Endovascular Femoropopliteal Stenting for Critical Limb Ischaemia.
    European journal of vascular and endovascular surgery : the official journal of the European Society for Vascular Surgery, 2017, Volume: 53, Issue:3

    Topics: Adult; Aged; Aged, 80 and over; Amputation, Surgical; Aspirin; Clopidogrel; Constriction, Pathologic

2017
Radiocephalic fistula complicated by distal ischemia: treatment by ulnar artery dilatation.
    Cardiovascular and interventional radiology, 2010, Volume: 33, Issue:1

    Topics: Aged; Angioplasty, Balloon; Arterial Occlusive Diseases; Catheters, Indwelling; Clopidogrel; Diabete

2010
Aortic thromboembolism successfully treated with anticoagulation and antiplatelet therapy.
    The American journal of medicine, 2009, Volume: 122, Issue:12

    Topics: Anticoagulants; Aorta, Thoracic; Arm; Clopidogrel; Coronary Artery Disease; Echocardiography, Transe

2009
Do not adjust the platelet count in light transmittance aggregometry when predicting thrombotic events after percutaneous coronary intervention.
    Journal of thrombosis and haemostasis : JTH, 2010, Volume: 8, Issue:10

    Topics: Angioplasty, Balloon, Coronary; Aspirin; Blood Platelets; Clopidogrel; Cohort Studies; Humans; Ische

2010
Endovascular management of patients with critical limb ischemia.
    Journal of vascular surgery, 2011, Volume: 53, Issue:4

    Topics: Aged; Aged, 80 and over; Amputation, Surgical; Angioplasty, Balloon; Boston; Clopidogrel; Critical I

2011
[Preoperative analysis of platelet aggregability in carotid surgery].
    No shinkei geka. Neurological surgery, 2011, Volume: 39, Issue:5

    Topics: Aged; Aged, 80 and over; Aspirin; Carotid Arteries; Clopidogrel; Endarterectomy, Carotid; Female; Hu

2011
Randomized controlled trial of dual antiplatelet therapy in patients undergoing surgery for critical limb ischemia.
    Annals of surgery, 2014, Volume: 259, Issue:2

    Topics: Aspirin; Female; Humans; Ischemia; Leg; Male; Platelet Aggregation Inhibitors; Ticlopidine

2014
Reply to letter: "Randomized controlled trial of dual antiplatelet therapy in patients undergoing surgery for critical limb ischemia".
    Annals of surgery, 2014, Volume: 259, Issue:2

    Topics: Aspirin; Female; Humans; Ischemia; Leg; Male; Platelet Aggregation Inhibitors; Ticlopidine

2014
Dose-dependent effect of early antiplatelet therapy in acute ischaemic stroke.
    Thrombosis and haemostasis, 2012, Volume: 107, Issue:1

    Topics: Adult; Aged; Aged, 80 and over; Aspirin; Body Mass Index; Brain Ischemia; Clopidogrel; Dose-Response

2012
Comparison of bolus only with bolus plus infusion of bivalirudin in patients undergoing elective percutaneous coronary intervention: a retrospective observational study.
    Journal of pharmacy practice, 2012, Volume: 25, Issue:5

    Topics: Aged; Alabama; Antithrombins; Aspirin; Clopidogrel; Dose-Response Relationship, Drug; Elective Surgi

2012
Combination of cilostazol and clopidogrel attenuates rat critical limb ischemia.
    Journal of translational medicine, 2012, Aug-16, Volume: 10

    Topics: Animals; Blotting, Western; Cilostazol; Clopidogrel; Drug Therapy, Combination; Extremities; Flow Cy

2012
Influence of ischemia before vein grafting on early hyperplasia of the graft and the dynamic changes of the intima after grafting.
    Journal of cardiothoracic surgery, 2012, Sep-24, Volume: 7

    Topics: Animals; Blood Vessel Prosthesis; Blood Vessel Prosthesis Implantation; Cell Proliferation; Clopidog

2012
Long-term results of plaque excision combined with aggressive pharmacotherapy in high-risk patients with advanced peripheral artery disease (SAVE a LEG registry).
    Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions, 2013, Sep-01, Volume: 82, Issue:3

    Topics: Adult; Aged; Aged, 80 and over; Amputation, Surgical; Aspirin; Atherectomy; Atorvastatin; Cardiovasc

2013
Acute peripheral arterial ischemia and suspected aortic dissection: usefulness of transesophageal echocardiography in differential diagnosis with aortic thrombosis.
    The American journal of cardiology, 2002, Sep-15, Volume: 90, Issue:6

    Topics: Acute Disease; Adult; Aged; Amputation, Surgical; Anticoagulants; Aortic Diseases; Arterial Occlusiv

2002
Protective effects of clopidogrel on oxidant damage in a rat model of acute ischemia.
    The Tohoku journal of experimental medicine, 2005, Volume: 205, Issue:2

    Topics: Animals; Clopidogrel; Disease Models, Animal; Glutathione; Ischemia; Male; Malondialdehyde; Oxidants

2005
Endovascular stent-assisted angioplasty in the management of traumatic internal carotid artery dissections.
    Stroke, 2005, Volume: 36, Issue:4

    Topics: Adult; Angiography; Angioplasty; Anticoagulants; Aspirin; Blood Platelets; Blood Vessel Prosthesis I

2005
Association of a functional polymorphism in the clopidogrel target receptor gene, P2Y12, and the risk for ischemic cerebrovascular events in patients with peripheral artery disease.
    Stroke, 2005, Volume: 36, Issue:7

    Topics: Aged; Alleles; Aspirin; Brain Ischemia; Cerebrovascular Circulation; Clopidogrel; Cohort Studies; Ex

2005
The antiplatelet effect of clopidogrel is not attenuated by statin treatment in stable patients with ischemic heart disease.
    Thrombosis and haemostasis, 2005, Volume: 94, Issue:2

    Topics: Aged; Atorvastatin; Blood Platelets; Cholesterol, LDL; Clopidogrel; Cytochrome P-450 CYP3A; Cytochro

2005
CHARISMA: the antiplatelet saga continues.
    Stroke, 2006, Volume: 37, Issue:9

    Topics: Atherosclerosis; Clinical Trials as Topic; Clopidogrel; Humans; Ischemia; Platelet Aggregation Inhib

2006
Surgical revascularisation in patients with severe limb ischaemia induces a pro-thrombotic state.
    Platelets, 2006, Volume: 17, Issue:5

    Topics: Aged; Aged, 80 and over; Antithrombin III; Arterial Occlusive Diseases; Aspirin; Blood Coagulation;

2006
[Cost-effectiveness of clopidogrel vs. aspirin treatment in high-risk acute coronary syndrome patients in Denmark].
    Ugeskrift for laeger, 2006, Aug-28, Volume: 168, Issue:35

    Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Coronary Artery Bypass; Coronary

2006
Clopidogrel-induced spontaneous spinal epidural hematoma.
    Journal of Korean medical science, 2007, Volume: 22, Issue:3

    Topics: Aged; Brain; Cerebral Angiography; Clopidogrel; Female; Hematoma, Epidural, Spinal; Humans; Ischemia

2007
ADP-induced platelet aggregation and platelet reactivity index VASP are good predictive markers for clinical outcomes in non-ST elevation acute coronary syndrome.
    Thrombosis and haemostasis, 2007, Volume: 98, Issue:4

    Topics: Acute Coronary Syndrome; Acute Disease; Adenosine Diphosphate; Aged; Blood Platelets; Cell Adhesion

2007
Intensifying platelet inhibition--navigating between Scylla and Charybdis.
    The New England journal of medicine, 2007, Nov-15, Volume: 357, Issue:20

    Topics: Acute Coronary Syndrome; Aspirin; Clopidogrel; Drug Therapy, Combination; Hemorrhage; Humans; Ischem

2007
Consensus document on intermittent claudication from the Central European Vascular Forum 1st edition - Abano Terme (Italy) - May 2005 2nd revision - Portroz (Slovenia) September 2007.
    International angiology : a journal of the International Union of Angiology, 2008, Volume: 27, Issue:2

    Topics: Aspirin; Carotid Stenosis; Clopidogrel; Disease Progression; Exercise Test; Humans; Intermittent Cla

2008
Effect of ticlopidine on the cutaneous circulation in peripheral vascular disease.
    Angiology, 1993, Volume: 44, Issue:8

    Topics: Aged; Blood Gas Monitoring, Transcutaneous; Drug Evaluation; Female; Gangrene; Humans; Intermittent

1993
Aspirin versus clopidogrel: the wrong question?
    Lancet (London, England), 1997, Mar-15, Volume: 349, Issue:9054

    Topics: Aspirin; Cerebrovascular Disorders; Clopidogrel; Humans; Ischemia; Myocardial Infarction; Platelet A

1997
Clopidogrel: a novel antiplatelet agent.
    Hospital medicine (London, England : 1998), 1999, Volume: 60, Issue:5

    Topics: Adenosine Diphosphate; Aspirin; Clopidogrel; Humans; Ischemia; Myocardial Infarction; Platelet Aggre

1999
Hereditary hemorrhagic telangiectasia, factor V Leiden and antiphospholipid syndrome: a case report.
    Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis, 2002, Volume: 13, Issue:1

    Topics: Antibodies, Anticardiolipin; Antiphospholipid Syndrome; Autoantibodies; Factor V; Female; Humans; Is

2002
[Validation of an automatic quantification system in angiography. Research group studying ticlopidine in atherosclerosis of the lower leg].
    VASA. Supplementum, 1989, Volume: 27

    Topics: Angiography; Arteriosclerosis; Femoral Artery; Humans; Iliac Artery; Ischemia; Leg; Models, Cardiova

1989